13.00 – 13.20

Welcome and introduction 

A. Petrolekas, Athens (GR) 

F. Sanguedolce, Bologna (IT)

Risk Reduction of Prostate Cancer: A new paradigm in Prostate Cancer Management*

13.20 – 13.40 

Risk reduction in general. The role of the risk reduction in prostate cancer

M. Marberger, Vienna (AT)

13.40 – 14.00

Is risk reduction for PCa worthwhile? 

P-A. Abrahamsson, Malmö (SE)

14.00 – 14.20

Can we identify the man at increased risk of developping PCa?

Which is currently the role of PSA in predicting PCa? 

P-A. Abrahamsson, Malmö (SE)

14.20 – 14.35 

Interactive question session 1

14.35 – 14.55

What is new in PCa risk reduction? 

M. Marberger, Vienna (AT)

14.55 – 15.10

Implications for clinical practice 

P-A. Abrahamsson, Malmö (SE)

15.10 – 15.25

Interactive question session 2

15.25 – 15.40

Summary and conclusion

M. Marberger, Vienna (AT)

15.40 - 15.50

Coffee break

Update on diagnosis and treatment of prostate cancer

15.50 – 16.10

Diagnosis and staging of prostate cancer. 

C. Oblak, Ljubljana (Sl)

16.10 - 16.30

Surgical treatment of prostate cancer: open versus laparoscopic versus robot 

assisted prostatectomy.   

P.J. Nyirády, Budapest (HU)

16.30 – 16.50

Quality of life after radical treatment  

I. Sinescu, Bucharest (RO)

16.50 – 17.10

Radiotherapy and hormonotherapy for prostate cancer 

M. Szücs, Budapest (HU)

17.10 - 18.00

Nightmare case discussion

18.00 - 18.10

Closing remarks 

T. Zober, Budapest (HU) 

S. Hruby, Vienna (AT)

* supported by an unrestricted education grant from GLAXOSMITHKLINE